Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates

Clinical Pharmacokinetics

Volumn 52, Issue 12, 2013, Pages 1127-1134

  Zhao, Wei ^a,b   Biran, Valérie ^a   Jacqz Aigrain, Evelyne ^a,b,c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; VANCOMYCIN;

AMIKACIN MATURATION MODEL; ANALYTICAL ERROR; ARTICLE; DRUG CLEARANCE; DRUG EXCRETION; EXPLORATORY RESEARCH; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DEVELOPMENT; MALE; MODEL; NEWBORN; PREDICTIVE VALUE; PRIORITY JOURNAL; SIMULATION;

AMIKACIN; ANTI-BACTERIAL AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; MALE; MODELS, BIOLOGICAL; VANCOMYCIN;

EID: 84890478559     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0101-6     Document Type: Article

References (43)

1. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-32.
2. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol. 2011;205:51-75.
3. Solhaug MJ, Bolger PM, Jose PA. The developing kidney and environmental toxins. Pediatrics. 2004;113(4(S)):1084-91.
4. Chen N, Aleksa K, Woodland C, et al. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006;21(2):160-8.
5. Jacqz-Aigrain E, Zhao W, Sharland M, et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med. 2013;18(1):28-34.
6. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-67.
7. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67-76.
8. Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29(3):284-91.
9. Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63(1):75-84.
10. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther. 1985;38(6):680-5.
11. De Cock RF, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105-17.
12. Pacifici GM. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol. 2009;65(4):419-27.
13. Panomvana D, Kiatjaroensin SA, Phiboonbanakit D. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime. Clin Pharmacokinet. 2007;46(10):859-66.
14. Bleyzac N, Varnier V, Labaune JM, et al. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol. 2001;57(6-7):499-504.
15. Tréluyer JM, Merlé Y, Tonnelier S, et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002;46(5):1381-7.
16. McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci. 2002;4(1):E4.
17. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931-56.
18. Zhao W, Lopez E, Biran V, et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449-53.
19. Knudsen JD, Fuursted K, Espersen F, et al. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother. 1997;41(9):1910-5.
20. Delattre IK, Musuamba FT, Verbeeck RK, et al. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clin Biochem. 2010;43(6):589-98.
21. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187-97.
22. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036-49.
23. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154-66.
24. Cella M, Knibbe C, Danhof M, et al. What is the right dose for children? Br J Clin Pharmacol. 2010;70(4):597-603.
25. Cella M, Gorter de Vries F, Burger D, et al. A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther. 2010;87(3):294-302.
26. Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child. 2008;93(3):207-11.
27. Barrett JS, Della Casa Alberighi O, Läer S, et al. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40-9.
28. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013-34.
29. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988;43(5):565-70.
30. Traynor J, Mactier R, Geddes CC, et al. How to measure renal function in clinical practice. BMJ. 2006;333(7571):733-7.
31. Swinkels DW, Hendriks JC, Nauta J, et al. Glomerular filtration rate by single-injection inulin clearance: definition of a workable protocol for children. Ann Clin Biochem. 2000;37(1):60-6.
32. van Rossum LK, Cransberg K, de Rijke YB, et al. Determination of inulin clearance by single injection or infusion in children. Pediatr Nephrol. 2005;20(6):777-81.
33. Bird NJ, Henderson BL, Lui D, et al. Indexing glomerular filtration rate to suit children. J Nucl Med. 2003;44(7):1037-43.
34. Stake G, Monclair T. A single plasma sample method for estimation of the glomerular filtration rate in infants and children using iohexol, I: establishment of a body weight-related formula for the distribution volume of iohexol. Scand J Clin Lab Invest. 1991;51(4):335-42.
35. Blake GM, Gardiner N, Gnanasegaran G, et al. Reference ranges for 51Cr-EDTA measurements of glomerular filtration rate in children. Nucl Med Commun. 2005;26(11):983-7.
36. Gutte H, Møller ML, Pfeifer AK, et al. Estimating GFR in children with 99mTc-DTPA renography: a comparison with single-sample 51Cr-EDTA clearance. Clin Physiol Funct Imaging. 2010;30(3):169-74.
37. Peake M, Whiting M. Measurement of serum creatinine - current status and future goals. Clin Biochem Rev. 2006;27(4):173-84.
38. van den Anker JN. Renal function in preterm infants. Eur J Pediatr. 1997;156(7):583-4.
39. Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2013;75(4):1068-80.
40. Delattre IK, Musuamba FT, Jacqmin P, et al. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin. Clin Biochem. 2012;45(10-11):780-6.
41. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56(2):169-75.
42. Allegaert K, Cossey V, Debeer A, et al. The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Pediatr Nephrol. 2005;20(6):740-3.
43. Schreuder MF, Wilhelm AJ, Bökenkamp A, et al. Impact of gestational age and birth weight on amikacin clearance on day 1 of life. Clin J Am Soc Nephrol. 2009;4(11):1774-8.